Research Associate

Elicio Therapeutics•Boston, MA

1d•$70,000 - $85,000•Onsite

About The Position

Reporting to the Scientist I/II and closely working with the Senior Research Associate I/II, this individual will serve as an integral team member in the Research Department with exposure to multiple facets of research operations including program discovery and development. The Research Associate will be responsible for executing and analyzing lab-based and small animal experiments. Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts with additional staff functioning in a virtual based environment from the Greater Boston area and throughout the United States. Major Duties/Responsibilities Executing and analyzing small animal experiments to evaluate immune responses to various antigen and adjuvant combinations (murine handling, injections, blood/organ collections, ex vivo tissue preparation and analysis) Executing and analyzing small animal experiments to evaluate anti-tumor activity of immunotherapy candidates (murine handling, tumor injections and monitoring, blood/organ collections, ex vivo tissue preparation and analysis) Executing assays to assess mechanisms of action underlying therapeutic activity Maintaining detailed and accurate records, data graphing and presentation Communicating findings in various forums both intra- and interdepartmentally Highly productive and comfortable in a fast-paced work environment Education & Professional Experience About Elicio Therapeutics Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer immunotherapy ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com. About the Amphiphile Platform Elicio Therapeutics’ proprietary Amphiphile (“AMP”) platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, Elicio has observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.

Requirements

Bachelor’s degree in biology or related discipline
Murine handling techniques and injections
Sample collection and processing: blood, spleen, lymph nodes, tumor, etc
Experience with murine syngeneic tumor models
Execution of ex vivo immuno-assays: multi-color flow cytometry, ELISpot/FluoroSpot, ELISA, Luminex, etc
Tissue culture (cell culture and aseptic technique, isolation of splenocytes or lymphocytes from murine samples)

Nice To Haves

Hands on experience with in vitrohuman immune cell assays a plus
Familiarity with pre-clinical drug development a plus

Responsibilities

Executing and analyzing small animal experiments to evaluate immune responses to various antigen and adjuvant combinations (murine handling, injections, blood/organ collections, ex vivo tissue preparation and analysis)
Executing and analyzing small animal experiments to evaluate anti-tumor activity of immunotherapy candidates (murine handling, tumor injections and monitoring, blood/organ collections, ex vivo tissue preparation and analysis)
Executing assays to assess mechanisms of action underlying therapeutic activity
Maintaining detailed and accurate records, data graphing and presentation
Communicating findings in various forums both intra- and interdepartmentally
Highly productive and comfortable in a fast-paced work environment